DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

Rhea-AI Summary

DBV Technologies (Nasdaq: DBVT) will present additional data from the positive VITESSE Phase 3 study of the VIASKIN Peanut Patch in children ages 4–7 at the AAAAI 2026 Annual Meeting in Philadelphia, Feb 27–Mar 2, 2026.

An oral abstract presentation is scheduled for Feb 28, 2:15–2:25pm ET, with a product theater on Feb 28, 10:00–10:30am ET featuring panelists discussing epicutaneous immunotherapy (EPIT) and early intervention. DBV will also exhibit at booth #1527.

Positive

• Positive VITESSE Phase 3 data for ages 4–7 presented at a major allergy meeting
• Oral abstract presentation on Feb 28, 2026 (2:15–2:25pm ET)
• Product theater panel on EPIT featuring renowned allergists on Feb 28, 2026
• Exhibit presence at booth #1527 for clinician and investor engagement

Negative

• None.

Key Figures

Responder rate (active): 46.6% Responder rate (placebo): 14.8% Responder rate difference: 31.8% +5 more

8 metrics

Responder rate (active) 46.6% VITESSE Phase 3 primary endpoint, VIASKIN Peanut

Responder rate (placebo) 14.8% VITESSE Phase 3 comparator arm

Responder rate difference 31.8% Active vs placebo difference; lower CI bound >15%

VITESSE enrollment 654 children Phase 3 VITESSE trial sample size

Treatment-related anaphylaxis 0.5% VITESSE safety outcome (n=2 cases)

Treatment compliance 96.2% VITESSE Phase 3 VIASKIN Peanut compliance rate

EPITOPE 3-year ≥1000 mg 83.5% Toddlers reaching eliciting dose ≥1000 mg at month 36

EPITOPE OFC completion 68.2% Completed oral food challenge without stopping criteria at month 36

Market Reality Check

Price: $22.60 Vol: Volume 342,792 is below t...

low vol

$22.60 Last Close

Volume Volume 342,792 is below the 20-day average of 499,773 (relative volume 0.69x). low

Technical Price 23.8 is trading above the 200-day MA at 12.92, indicating a pre-existing uptrend.

Peers on Argus

DBVT is up 4.52% while peers show mixed, smaller moves (e.g., CADL up 0.52%, OME...

DBVT is up 4.52% while peers show mixed, smaller moves (e.g., CADL up 0.52%, OMER down 1.5%, ANNX down 1.58%), suggesting a stock-specific reaction.

Previous Clinical trial Reports

4 past events · Latest: Dec 16 (Positive)

Same Type Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Dec 16	Phase 3 topline data	Positive	-1.7%	Positive Phase 3 VITESSE topline results for VIASKIN Peanut in children 4–7.
Nov 11	Trial milestone	Positive	-1.8%	Completion of last patient visit in VITESSE Phase 3 peanut allergy trial.
Jan 08	Long-term efficacy data	Positive	+29.8%	Positive three-year EPITOPE Phase 3 extension results for VIASKIN Peanut in toddlers.
Sep 23	Enrollment completion	Positive	+4.3%	Completion of screening and exceeding recruitment goals for VITESSE Phase 3 trial.

Pattern Detected

Clinical trial updates have produced mixed reactions: major positive data sometimes saw selling, while other positive readouts and milestones were rewarded.

Recent Company History

Over the last year, DBV’s key news flow has centered on VIASKIN Peanut clinical progress. Events include completing VITESSE screening in Sep 23, positive three-year EPITOPE extension data on Jan 08, last patient visit completion in VITESSE on Nov 11, and positive VITESSE topline results on Dec 16. Price reactions to these clinical milestones have alternated between gains and declines, indicating that even constructive data do not always translate into immediate share appreciation.

Historical Comparison

clinical trial

+7.6 %

Average Historical Move

Historical Analysis

In the past year, DBVT released 4 clinical trial updates with an average move of 7.64%. Today’s conference-focused update fits into this pattern of data-driven catalysts around VIASKIN Peanut.

Typical Pattern

Clinical news shows steady progression of VIASKIN Peanut, from VITESSE enrollment completion through last patient visits and positive topline data, alongside long-term EPITOPE extension results.

Market Pulse Summary

This announcement highlights additional VITESSE Phase 3 data and scientific visibility for the VIASK...

Analysis

This announcement highlights additional VITESSE Phase 3 data and scientific visibility for the VIASKIN Peanut patch in children aged 4–7 at the AAAAI 2026 meeting. It builds on earlier positive VITESSE and EPITOPE results that showed strong responder rates and favorable safety. Historically, DBV’s clinical milestones have produced varied share reactions, so future updates on regulatory timelines, longer-term outcomes, and presentation details will be important reference points for assessing the program’s trajectory.

Key Terms

epicutaneous immunotherapy, EPIT, Phase 3

3 terms

epicutaneous immunotherapy medical

"discussing the potential of epicutaneous immunotherapy (EPIT) to reeducate the immune system"

Epicutaneous immunotherapy is a treatment that delivers tiny, controlled doses of an allergen through a patch applied to the skin to retrain the immune system and reduce allergic reactions over time. Think of it as a slow, measured exposure training the body to tolerate a trigger rather than avoiding it entirely. Investors watch this approach because it represents a potentially safer, easier-to-administer alternative to injections or pills, with implications for market size, regulatory approval, and long-term treatment adoption in allergy therapeutics.

EPIT medical

"Epicutaneous Immunotherapy (EPIT): Shaping the Future of Pediatric Food Allergy Treatment"

Epit stands for epicutaneous immunotherapy, a medical approach that delivers tiny amounts of an allergen through a skin patch to teach the immune system to tolerate it over time. For investors, EPIT matters because it represents a non‑invasive, potentially lower‑cost and safer way to treat allergies that can broaden patient adoption, influence clinical development and approval timelines, and affect a product’s commercial reach—like gradually desensitizing someone with controlled, small exposures rather than a sudden large dose.

Phase 3 medical

"additional data from the VITESSE Phase 3 Study of the VIASKINae Peanut Patch"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. Not financial advice.

Châtillon, France, February 10, 2026

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the company will present additional data for the VIASKIN® Peanut Patch in children ages 4-7 years from the positive VITESSE Phase 3 study at the American Academy of Allergy, Asthma, and Immunology 2026 Annual Meeting, taking place in Philadelphia, PA February 27-March 2, 2026.

The Company will also host a product theatre featuring a panel of renowned allergists discussing the potential of epicutaneous immunotherapy (EPIT) to reeducate the immune system in food allergy, examine the impact of early intervention in children with peanut allergy, and consider how emerging treatment options are enabling for a more proactive approach to peanut allergy management.

Oral Abstract Presentation Details
“VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age”

• Session: Clinical Science in Food Allergy
• Date and Time: February 28, 2026, 2:15-2:25pm ET
• Location: Level 4, Terrace Ballroom II
• Presenter: David Fleischer, MD, FAAAAI, FACAAI

Product Theater Details
“Epicutaneous Immunotherapy (EPIT): Shaping the Future of Pediatric Food Allergy Treatment”

• Date and Time: February 28, 2026, 10:00-10:30am ET
• Location: Level 2, Hall E
• Participants: Hugh Sampson, MD, Katherine Anagnostou, MD, MSc, PhD, S. Shahzad Mustafa, MD
  
  

DBV will exhibit at booth #1527 in the AAAAI exhibit hall where attendees can learn more about epicutaneous immunotherapy and the VIASKIN^® Peanut Patch.

About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of VIASKIN® Peanut patch and EPIT, results of DBV’s clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans and expectations with respect to the submission of BLAs to FDA, and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 11, 2025, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 28, 2025, and as amended further by Amendment No. 2 on Form 10-K/A filed with the SEC on May 14, 2025, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

VIASKIN is a registered trademark of DBV Technologies.

Investor Relations Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com

Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com

Attachment

• PDF Version

FAQ

What will DBV Technologies present about the VITESSE Phase 3 study at AAAAI 2026 (DBVT)?

DBV will present additional data from the positive VITESSE Phase 3 study in children ages 4–7. According to DBV, the oral abstract is scheduled Feb 28, 2:15–2:25pm ET and will cover efficacy and safety findings for the VIASKIN Peanut Patch.

When and where is DBV's oral abstract presentation on VIASKIN Peanut Patch (DBVT)?

The oral abstract is scheduled for Feb 28, 2026 from 2:15–2:25pm ET in Level 4, Terrace Ballroom II. According to DBV, David Fleischer, MD, will present results from the VITESSE Phase 3 study in children ages 4–7.

What is the focus of DBV's product theater on EPIT at AAAAI 2026 (DBVT)?

The product theater will discuss epicutaneous immunotherapy and early intervention for pediatric peanut allergy. According to DBV, the session on Feb 28 at 10:00am ET features a panel of leading allergists examining EPIT's role in treatment strategies.

How can clinicians and attendees learn more about VIASKIN Peanut Patch at AAAAI 2026 (DBVT)?

Attendees can visit DBV at exhibit booth #1527 and attend the oral abstract and product theater sessions. According to DBV, the exhibit and sessions provide clinical details and discussion on EPIT and the VIASKIN Peanut Patch program.

Who are the presenters and panelists for DBV's sessions on EPIT at AAAAI 2026 (DBVT)?

The oral presentation will be delivered by David Fleischer, MD; the product theater panel includes Hugh Sampson, MD, Katherine Anagnostou, MD, MSc, PhD, and S. Shahzad Mustafa, MD. According to DBV, these clinicians will discuss EPIT and pediatric treatment implications.